LVYE pharmaceutical acquires two monoclonal antibody drugs under development

December 21, 2018 / Meitong news agency / -- LVYE Pharmaceutical Group announced the acquisition of two biological antibody drugs under development of Shandong Boan Biotechnology Co., Ltd At present, green leaf pharmaceutical has been in the field of biopharmaceutical multi line layout, domestic and overseas research and development of a number of biological antibody drugs are progressing smoothly As one of the business focus of future development, the company will continue to increase R & D investment in this field, accelerate the global layout of biological drugs, and add new driving force for future performance growth The acquired two biological antibody drugs ly01011 and ly09004 are monoclonal antibody drugs Among them, ly01011 is a recombinant anti RANKL all human monoclonal antibody injection, a biological analogue of xgeva, which is used to treat multiple myeloma and bone metastasis caused by solid tumor At present, the drug has obtained clinical approval and is about to enter phase I clinical; ly09004 is a recombinant human vascular endothelial growth factor receptor antibody fusion protein eye injection, which is a biological analogue of eyla Its indications include neovascular (wet) senile maculopathy, macular edema after retinal vein occlusion, diabetic macular edema, and diabetic macular edema Diabetic retinopathy of the patient The drug has been declared for clinical use Today, biopharmaceuticals have become an important part of the global pharmaceutical industry and a driving force for growth Public data shows that from 2016 to 2022, the global biopharmaceutical market is expected to grow from US $2020 billion to US $326 billion, with a compound annual growth rate of 8.3% Not only that, biopharmaceutical industry has become one of the most growing industries in China's pharmaceutical industry From 2012 to 2016, the compound annual growth rate of domestic biopharmaceutical market is as high as 24.9%, and it is expected to reach the market scale of 326.9 billion yuan in 2021 According to the two products purchased by LVYE pharmaceutical, the global sales of the market comparable product xgeva of ly01011 reached USD 1.575 billion in 2017, and the global sales of the comparable product eylea of ly09004 reached USD 5.929 billion in 2017 The company's management is very optimistic about the market prospects of these two drugs From the perspective of the company's strategic development, the addition of ly01011 can further expand the company's product line in the field of cancer Ly09004 is expected to be widely used in the treatment of elderly patients with wet macular degeneration and diabetic macular edema, which can significantly correct the visual sensitivity of macular edema, improve the second stage of central retinal vein occlusion, and help the company enter the field of eye treatment 。 In 2017, green leaf pharmaceutical launched the research and development of biotechnology drugs at home and abroad simultaneously, and established the development platform of biological antibody technology In the second half of 2017, LVYE pharmaceutical purchased two other biological antibody products ly01008 (biological analog of Avastin) and ly06006 (biological analog of Prolia) from Shandong Boan Biotechnology Co., Ltd At present, the two drugs have entered phase III and phase I clinical respectively in China, and the research and development progress is smooth In addition, green leaf pharmaceutical has continued to increase the research and development and supply of new drugs in the field of Biopharmaceutics through cooperative research and development At the end of last year, LVYE pharmaceutical signed a cooperation agreement with abpro, a comprehensive life science company at the forefront of synthetic biology, to jointly research, develop and commercialize new bispecific antibody products in the field of tumor immunology; in the first quarter of this year, LVYE pharmaceutical and excel biopharm, a biotechnology company in California, USA LLC signed a cooperation agreement to jointly develop therapeutic antibodies for the next generation of tumor immunotherapy.